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 Methyl-CpG-binding protein 2 (MeCP2 is) is an epigenetic regulator that binds to 
methylated DNA.  Initially identified as transcriptional repressor, MeCP2 also binds to different 
proteins functioning as gene activator. Importantly, MecCP2 gene mutations and changes in 
MeCP2 levels are associated to several forms of mental retardation and autism-related disorders; 
including Rett, a neurodevelopmental disorder affecting primarily girls. While brain MeCP2 was 
considered to be exclusively neuronal, this regulator is also present in glia.  We found that 
oligodendrocytes, the myelinating cells of the central nervous system (CNS), express particularly 
high MeCP2 levels at a developmental stage that precedes their final maturation.  Moreover, 
xi 
downregulation of MeCP2 levels by treatment of immature oligodendrocytes with small 
interference RNA (siRNA), reduced the expression of 14 kDa myelin basic protein (MBP) and 
MOG, two markers of mature oligodendrocytes. These observations raise the possibility that 
oligodendrocytes have a direct participation in Rett syndrome and other autism-related disorders. 
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Introduction 
 
 Since the 19th century, when Golgi and Ramón y Cajal first described them, the cells 
of the mammalian nervous system have captivated neuroscientists.  Over the course of the past 
century and a half of cellular neuroscience research, the neuronal doctrine has dominated the 
study of the brain.  Essentially, neurons were identified as the functional elements of the nervous 
system, while the glial cells were merely regarded as support for these highly specialized cells.  
In recent years this dogma has been called into question; it is now well known that glial cells are 
far more than just the “glue” that holds the nervous tissue together, supplying energy and 
neurotrophic factors, regulating axonal growth and modulating synaptic plasticity and neuronal 
function (Fields 2006). 
 Among the glial cells are the oligodendrocytes, the cells responsible for the synthesis 
of the myelin membrane in the CNS.  These cells have been implicated in the pathogenesis of a 
number of illnesses of the CNS, including among others multiple sclerosis, leukodystrophy, 
schizophrenia and autism.  Rett syndrome, first described by Andreas Rett in 1966, is a 
neurodevelopmental disorder in which girls between 6 and 18 months of age develop profound 
mental retardation and other neurological maladies.  This syndrome results from mutation of the 
gene encoding MeCP2 (Amir et al. 1999), a protein initially thought to be solely localized in 
neurons(Shahbazian et al. 2002).  As later described in this thesis, altered expression of this 
protein is also observed in some cases of autism and other related neurodevelopmental disorders.  
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 Studies presented in this thesis confirmed the presence of MeCP2 in developing 
oligodendrocytes and began to investigate the role of this transcriptional regulator in potentially 
controlling myelination. Our results indicated that MeCP2 is an important player in the 
mechanisms that control oligodendrocyte development, a finding that has direct implications for 
the understanding of Rett syndrome and autism-related disorders also associated with abnormal 
MeCP2. 
   
The myelin membrane  
Myelin structure and function 
 Myelin is a highly specialized multilamellar membrane structure that wraps around 
the axons of the nervous system in successive concentric layers, akin to paper spirally rolled 
around a tube.  Generated by the Schwann cells in the PNS and oligodendrocytes in the CNS 
(Bunge 1968; Baron and Hoekstra 2010); the myelin membrane insulates the axons and 
facilitates the rapid conduction of action potentials along the fibers.  Myelin exists in almost all 
vertebrates, with the exception of the agnathans (jawless fishes) (Waehneldt 1990), and as 
described later, recent research on the etiology of different diseases suggests that this membrane 
also plays a crucial role in CNS development and plasticity.  The following sections will discuss 
in detail the structure, electrophysiology, and molecular composition of the myelin membrane. 
 
Myelin Structure 
  Myelin is a specialized structure formed by the extension and concentric wrapping of 
axons by Schwann cell membrane in the PNS or the extended process of an oligodendrocyte in 
the CNS [Fig. 1]. As myelination occurs, extrusion of the glial cytoplasm and subsequent 
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compaction of the wrapping membrane results in the formation of a continuous multilamellar 
sheath or “myelin internode”. These myelin segments are 150-200µm in length (Butt and 
Ransom 1989), and alternate with “Nodes of Ranvier”, intercalating unmyelinated sections of 
the axons which vary in length according to their location in the CNS (Bjartmar et al. 1994),  and 
at which sodium selective voltage-gated ion channels cluster.  The region directly adjacent to the 
Node of Ranvier is the paranode, characterized by loops of uncompacted myelin membrane.  
These paranodal loops are tethered to the axolemma by intermembrane proteins that include 
Caspr (paranodin), contactin, and neurofascin-155 (NF-155) (Einheber et al. 1997; Menegoz et 
al. 1997; Charles et al. 2002).  On the other hand, the myelinated section of the axon between the 
paranode and the internode is termed the juxtaparanode, and is characterized by a high 
concentration of potassium ion channels in the axonal membrane.  As described later, this 
regionalization of ion channels plays a highly important role in the function of the myelinated 
axon. 
 Interestingly, several lines of evidence have shown that myelin and oligodendrocytes 
are both involved in the induction and/or maintenance of the different axonal domains and their 
characteristic ion channel distribution (Rasband and Trimmer 2001a; DUPREE et al. 2004; Pillai 
et al. 2009; Thaxton et al. 2011). 
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Figure 1: A) Depiction of an oligodendrocyte extending processes to different axons.  Note that 
each process forms a single myelin internode, adjacent internodes can be formed by different 
oligodendrocytes [not shown].  Modified from Science Photo Library 
http://www.sciencephoto.com  B) Diagram of a single myelin segment that has been unwound 
from an axon.  Oligodendrocytes in culture will form similar uncoiled structures, called leaflets.  
The outer edges of the leaflet contain uncompacted cytoplasm, permitting the transfer of 
material.  Modified from Basic Neurochemistry, edited by Siegel, Albers, Brady, and Price, 
Elsvier, 2006.  C)  An alternate depiction of a myelinating oligodendrocyte.  Nodes of Ranvier 
are naked axonal regions limited by successive myelin sheaths.  Modified from Canadian 
Institutes of Health Research: Institute of Neurosciences, Mental Health and Addiction 
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 The formation of myelin is a highly regulated process, with different areas of the 
CNS having different degrees of myelination, as well as different classes of nerve fibers showing 
distinct patterns of myelination. Importantly, both myelin formation and axonal growth are 
thought to be tightly coordinated by axo-glial interactions (Waxman and Sims 1984; Baumann 
and Pham-Dinh 2001).   During development, maturing myelinated axons experience a 
remarkable increase in radial growth. Interestingly, this dramatic growth is restricted to the 
myelinated areas of the axons and its induction has been attributed to the myelinating glial cells 
(de Waegh et al. 1992; Colello et al. 1994; Sanchez et al. 1996a).   The molecular mechanisms 
that control this glial function are not fully understood, however certain interactions have been 
characterized.  Larger axons have thicker myelin sheaths, and the thickness of the myelin sheath 
on an individual axon is believed to be regulated by axo-glial interactions (Waxman and Sims 
1984; Baumann and Pham-Dinh 2001).  The extracellular integrin β1 has been shown to have a 
role in initiating the process of myelination (Câmara et al. 2009).  It has also been noted that 
electrical activity along the axon appears to be required for proper myelination (Zalc and 
Douglas Fields 2000; Fields 2005) and that oligodendrocytes respond to different 
neurotransmitters in a developmentally regulated manner (Sato-Bigbee et al. 1999a), 
observations that further emphasize the importance of axo-glial communications. 
 
Electrophysiology of Myelinated Axons  In the nervous system, action potentials are 
propagated along axons, allowing transmission of electrical signals over exceedingly long 
distances.   The plasma membrane surrounding all animal cells allows the separation of charge 
between the extracellular and intracellular environment.  By wrapping the axons of the nervous 
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system in successive layers of insulating lipid bilayer, myelin allows for greater conduction 
speeds.  The equation CV= 1/ [Cm·√(Rm·Rin)] relates conduction velocity (CV) with membrane 
capacitance (Cm), membrane resistance (Rm) and cytosolic resistance (Rin).  Decreased 
capacitance of the axolemma due to the presence of the myelin membrane allows a substantial 
increase in conduction velocity.  The myelinated axon magnifies the effect of small changes in 
ion concentrations, ionic charges are not balanced by opposing charges outside the myelin sheath 
and current is thus quickly transmitted from node to node, which has the result of increasing 
conduction velocity.  This phenomenon is known as “saltatory” (from the Latin ‘saltare’: to hop) 
conduction, so called because the membrane depolarization “hops” from one Node of Ranvier to 
the next, rather than gradually moving down the entire length of the axonal membrane (Tasaki 
1939; Huxley and Stämpeli 1949).  The end result of this adaptation is signal conduction along 
an axon at an incredible speed, allowing electrochemical messaging to rapidly proceed through 
the nervous system.  CV is directly related to axon diameter.  In unmyelinated axons, this is 
given by the equation CV=√d where d=axon diameter.  In myelinated axons, the equation is 
CV=d. 
 As described before, the ion channels that permit ion flow across the axolemma 
exhibit a highly segregated localization along the axon.  K+-selective channels are localized to 
the juxtaparanode (Wang et al. 1993).  On the other hand, Na+-selective channels are localized 
within the nodal region itself (Shrager 1989).  This localization, coupled with the insulation 
provided by myelin, allows for the rapid changes in membrane voltage to be localized to the 
Nodes of Ranvier.  The reduced capacitance of the myelinated axon means that small changes in 
ion concentrations on either side of the membrane result in large changes in voltage for the entire 
length of the internode, this increases the efficiency of the system as compared to an 
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unmyelinated axon.   First, the aggregate number of ions that must be moved back across the 
axolemma is substantially reduced.  Multiple discharges are possible with less energy required to 
transport ions against their concentration gradients, and less time required to repolarize the axon 
following an action potential.  The efficiency of unmyelinated axons is much reduced, as far 
greater concentrations of Na+/K+ ions must be transported against their concentration gradients to 
repolarize the axonal membrane after each action potential, necessitating the use of more Na+/K+ 
active transporter proteins, and the expenditure of far more energy in the form of ATP as 
compared to myelinated axons (Richie 1973; Wang et al. 2008).   It is also important to point out 
that insulation by myelin, which facilitates rapid conduction with relatively smaller caliber 
axons, together with the capacity of a single oligodendrocyte to myelinate multiple internodes 
and axons, allows for maximal efficiency in the restricted space available for the CNS.   
 
Myelin Composition and Structure 
 As indicated above, myelin can be considered as an extension of the Schwann cell or 
oligodendroglial plasma membrane. However, unlike most biological membranes, myelin 
contains a very high proportion of lipids (70-80% of dry weight) and a low amount of proteins 
(20-30%).   Cholesterol is present in a far higher molar ratio in myelin than in other tissues of the 
body (Baumann and Pham-Dinh 2001). Myelin also has a high content of phospholipids and is 
particularly enriched in glycolipids, predominantly galactocerebrosides (GalC) and their sulfated 
derivatives, sulfatides (Jahn et al. 2009). 
  When viewed in cross-section through an electron microscope, layers of myelin can 
be visualized as alternating thick (major dense) and thin (intraperiod) lines (Sjostrand 1950).  
The major dense line is generated from the extrusion of cytoplasm and close contact of the 
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intracellular sides of the rolling membrane.  The intraperiod line consists of the apposed 
extracellular surfaces of adjacent myelin wraps.  The periphery of each myelin leaflet is 
uncondensed, allowing metabolites to move within the sheath. 
 Myelin basic protein (MBP) is essential for the formation of compact myelin (Privat 
et al. 1979); it localizes to the intracellular surface of the myelin membrane and contributes to 
the stability of the myelin sheath.  MBP is used as a marker to label myelinating 
oligodendrocytes, and comprises up to 30% of the protein content of myelin.  The protein binds 
to negatively charged lipids present on the inner leaflet of the plasma membrane and this is 
thought to contribute to myelin compaction.  There are several MBP isoforms resulting from 
alternative splicing of a single gene called Golli-MBP. This is one of the most complex 
mammalian genes, containing a minimum of three transcription start sites and ten exons (Pribyl 
et al. 1993).  Interestingly, some of the proteins encoded by the Golli-MBP gene are not 
localized to the myelin membrane or the oligodendrocytes but to neurons and cells of the 
immune system. DNA transcribed from start site 3 usually encodes MBP proteins.  While the 
significance of the different MBPs is not fully understood, it is known that these isoforms are 
differentially expressed during development and also exhibit differential intracellular 
localization.  Isoforms containing exon II of the MBP gene do localize to the nucleus and the 
cytoskeleton, while exon II-lacking isoforms are primarily found in the myelin membrane 
(Baumann and Pham-Dinh 2001).  During active myelination, MBP synthesis is rapidly 
upregulated and MBP mRNAs destined to generate isoforms localized in myelin are transported 
along the oligodendrocyte processes to the distant sites of translation to facilitate local membrane 
production (Ainger et al. 1993; Boggs 2006; Min 2009; Laursen et al. 2011). Multiple animal 
models exist in which the MBP encoding regions have been subject to insertion, deletion and 
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substitution mutations, showing that the MBP gene is necessary for myelination, but not 
necessary for oligodendrocyte development (Privat et al. 1979).   
 Another major component of myelin is the transmembrane proteolipid protein (PLP), 
which constitutes about 50% of the total myelin protein.  The extracellular domains of PLP serve 
as linkages that tightly bind together the apposed extracellular surfaces of the layers of myelin 
(Klugmann et al. 1997). 
  Myelin-associated glycoprotein (MAG) is a type I transmembrane glycosylated 
protein present in myelinating cells and periaxonal layer of the myelin membrane. This heavily 
glycosylated protein is believed to have a role in glial-axonal interactions.  MAG has been shown 
to be important for the maintenance of myelinated axons; its absence results in a reduction of 
axonal caliber, neurofilament spacing, and neurofilament phosphorylation (Yin et al. 1998b).   
MAG also functions as an inhibitor of neurite outgrowth in white matter, and acts as a ligand for 
the Nogo receptor on neurons, inhibiting axonal regeneration (Filbin 1996).    
 Another glycoprotein, myelin/oligodendrocyte-associated glycoprotein (MOG) is like 
MAG a member of the immunoglobulin superfamily. Both MOG and MAG are expressed in the 
oligodendrocytes themselves, but unlike the periaxonal location of MAG, MOG is present on the 
external surface of the myelin sheath (Pham-Dinh et al. 1993).  MOG’s exact function is still 
unclear, though evidence has lead to three likely roles, that of a surface adhesion/receptor 
molecule, a regulator of oligodendrocyte microtubule stability via MBP degradation, or as an 
activator of complement in the CNS(Johns and Bernard 1999).   
   
Myelin in Disease 
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 Myelin is critical for the normal function of the nervous system.  Moreover the 
process of myelination is highly interconnected with plasticity and remodeling of the developing 
brain. The original perception of myelin as an inert insulating structure only responsible for 
saltatory conduction has radically changed to that of a complex membrane which, as mentioned 
above, is also implicated in controlling axonal extension and radial growth (Yin et al. 1998a), 
axolemmal integrity (Bruce et al. 2010), and the establishment of nodal and paranodal structures 
and ion channel localization at the nodes of Ranvier (Rasband and Trimmer 2001b).  Results 
from different laboratories also indicate that the oligodendroglial cells themselves could regulate 
axonal function by maintaining bidirectional glial-neuronal interactions (Fields 2008). Moreover, 
in agreement with a large number of animal studies, there is evidence correlating increased 
myelin formation with experience and enhanced function of the infant brain (Als et al. 2004; 
Pujol et al. 2006). It is known that human cognitive development and memory as well as learning 
experience beyond early infancy are positively correlated with white matter deposition in 
functionally related areas of the brain (Bengtsson et al. 2005; Deutsch et al. 2005; Niogi and 
McCandliss 2006; Whitaker et al. 2008; Rimrodt et al. 2010; Takeuchi et al. 2010; Uhlhaas et al. 
2010).  Furthermore, the importance of myelin in the later phases of brain maturation is also 
underscored by the growing number of neurological diseases being associated to white matter 
pathology during adolescence, including among others schizophrenia (Chambers and Perrone-
Bizzozero 2004; Kubicki et al. 2005; Kerns et al. 2010; Whitford et al. 2010), bipolar disorder 
(Chambers and Perrone-Bizzozero 2004; Brambilla et al. 2009; Mahon et al. 2010), and autism 
(O'Hearn et al. 2008).   
 Disease states that are associated with demyelination include multiple sclerosis, 
leukodystrophy, transverse myelitis, and optic neuritis.  The classic example of a demyelinating 
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disease is multiple sclerosis (MS), in which lesions are present in the white matter of the CNS.  
Disruption of the myelin sheath on the axons of the CNS cause the symptoms of MS, including 
muscle weakness, clonus, and ataxia.  At the cellular level, demyelination can result in 
conduction failure as demyelinated axons in the CNS fail to conduct action potentials; 
additionally, in silico modeling suggests that demyelination may be responsible for spontaneous 
discharges of the axon (Coggan et al. 2010).  In response to the loss of myelin, ion channels 
begin to diffuse from their previously well defined areas and propagate throughout the 
membrane of the axon, allowing action potentials to traverse the demyelinated axonal membrane, 
though at a far reduced conduction velocity (Bostock and Sears 1978). 
 Potential therapies for these diseases are aimed at remyelination by the 
oligodendrocytes and therefore, understanding the biology of these cells is of significant 
importance.   
   
Oligodendrocytes 
 Virchow first identified the glial cells as a novel category of nervous system cells in 
the mid-19th century.  He described these cells as “nervenkitt” (neural putty), or glia.  Rio 
Hortega coined the term ‘oligodendroglia’ in the early 20th century to describe a population of 
neuroglial cells with a few processes.  As exploration of the CNS progressed, scientists theorized 
that these glial cells were a support system for the highly specialized neurons.  Thus, for more 
than a century, the neuron was considered to be the functional unit of the nervous system.  
However, in recent years this dogma has been challenged by findings from numerous 
laboratories indicating that glial cells, including oligodendrocytes, astrocytes and microglia, play 
multiple and crucial functions in the CNS.   
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 As described before, Oligodendrocytes are responsible for the synthesis of myelin in 
the CNS.  Additionally, oligodendrocytes have been shown to have a role in axonal growth and 
maintenance, and inhibition of axonal regeneration, through surface-surface receptor interactions 
(Sanchez et al. 1996b).  Moreover, a recent report indicated an important function of 
oligodendrocytes in the establishment of neuronal networks during early development of the 
brain  (Doretto 2011). 
  Several new studies have also discovered that glial cells in the white matter of rat 
brain and spinal cords are interconnected by gap junctions comprised of apposed connexin 
membrane proteins.  These junctions, which permit the flow of water, ions, and proteins between 
cells, join oligodendrocytes and astrocytes in the so called “paraglial syncitium”. There is 
documented evidence for the existence of both astrocyte-astrocyte as well as astrocyte-
oligodendrocyte connections (Rash et al. 1997).  Oligodendrocyte-oligodendrocyte connections 
have recently been characterized and while their functional significance is not known at this 
time, some may play a role in modulating local ion concentrations around Nodes of Ranvier 
(Yamazaki et al. 2007).  Importantly, many of the myelin-associated diseases described above, 
including multiple sclerosis, schizophrenia, leukodystrophies, and leukoencephalopathies also 
affect the oligodendroglia (Baumann and Pham-Dinh 2001). The following sections will describe 
the development of oligodendrocytes as understanding of these cells' biology may be crucial to 
the design of therapies for myelin-related diseases. 
 
Oligodendrocyte development 
 Oligodendrocytes have multiple processes extending from a central soma, in vivo 
each of these cell processes has the potential of wrapping around an axon, forming a single 
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internodal segment of myelin sheath.  However, a single oligodendrocyte may extend processes 
to and myelinate up to 10-50 different axons.  In addition to those that myelinate axons, there are 
smaller satellite oligodendrocytes present in the white matter as well.  Although the precise 
function of these cells remains unknown (Nishiyama 1999), several lines of evidence suggests 
that these cells function in remyelination in disorders like multiple sclerosis (Reynolds et al. 
2002). 
 It is important to stress that while each Schwann cell generates a single myelin 
internode in a single axon, a single oligodendrocyte can myelinate multiple neurons and form 
several myelin segments (Peters 1964).  Therefore death of a single oligodendrocyte can generate 
areas of demyelination on multiple axons.  Additionally, oligodendrocytes exhibit several unique 
characteristics that make them susceptible to injury.  Evidence of this is seen in demyelinating 
mouse models, mice treated with the copper-chelating agent cuprizone and immuno-mediated 
models of demyelination (Matsushima and Morell 2001). 
 Oligodendrocyte lineage is traced to the neuroectodermal cells of the developing 
mammalian embryo, sharing an initial developmental pathway with neurons and astrocytes.  
Oligodendrocyte precursor cells (OPCs) are mitotically active and characterized by a bipolar 
morphology and migratory behavior.  OPCs migrate from origin sites within the dorsal spinal 
cord and the ventricular and subventricular zone (SVZ) of the mammalian brain, migrating to 
their final destinations guided by various extracellular molecules (Small et al. 1987; Ffrench-
Constant 1988).  Prior to their maturation into cells capable of myelination, OPCs must undergo 
several steps of development (Figure 2).  Immunostaining techniques are highly effective means 
of both identifying oligodendrocytes and determining their maturational stage.  A number of 
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distinct phenotypic stages have been identified based on the expression of various specific 
antigenic markers.  
 Early proliferative OPCs are bipolar cells that express the NG2 chondroitin sulfate 
proteoglycan and the platelet-derived growth factor alpha receptor (PDGFr-α) (Levine et al. 
1993; Nishiyama et al. 1996; Chang et al. 2000) These immature cells can also be labeled with 
the A2B5 antibody that recognizes several gangliosides including GT3 and its O-acetylated 
derivative (Dubois et al. 1990; Farrer and Quarles 1999) . Those antigens are down-regulated as 
the cells differentiate into committed oligodendrocytes which are multipolar and can be labeled 
with both the O4 and O1 antibodies, which react with sulfatides and GalC, respectively (Sommer 
and Schachner 1981). In the next stage, cells are additionally labeled with antibodies against 2’, 
3’-cyclic nucleotide 3’-Phosphodiesterase (CNPase), a myelin-associated enzyme known to be 
expressed at high levels almost exclusively in both Schwann cells and oligodendrocytes 
(Baumann and Pham-Dinh 2001).  Over-expression of this protein causes a variety of myelin 
defects in the developing brain(Gravel et al. 1996).  The final stage of differentiation is 
characterized by the expression of other myelin proteins, including PLP, the MBPs, MAG and 
MOG (Kumar et al. 1988). 
 Like astrocytes, oligodendrocytes mature mostly in the postnatal period of 
mammalian animals.  Importantly, some populations of OPCs do not continue down the path of 
differentiation, and remain as OPCs in the SVZ.  It is hypothesized that these cells may serve to 
repair demyelinated axons.  Remyelination in cuprizone treated mice has been shown to occur in 
waves, in which NG2+ cells migrate to sites of demyelination and metamorphose into mature 
oligodendrocytes (Mason et al. 2000). 
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 At the final stage of maturation, the cells begin to rapidly synthesize the components 
of the myelin membrane.  In vitro the multiple branching processes formed in the premature 
phase begin to form characteristic leaflets, broad sheets of myelin membrane.  In vivo these same 
cells will begin to sheathe the axons of neurons with their leaflets, as will oligodendrocytes co-
cultured with neurons. 
 MBP, as previously mentioned, is generated from the Golli-MBP gene in a number of 
different splicing isoforms and appears to have a crucial role in myelin compaction.  The 
positively-charged lysine and arginine residues of MBP tightly bind to negatively-charged 
phosphatidyserine, a lipid which is present on the intracellular plasma membrane leaflet of 
oligodendrocytes causing apposed inner-membrane leaflets to be drawn together and facilitating 
the compaction of myelin(Min 2009).  It is believed that Translation of MBP mRNA must 
therefore occur near the site of myelin synthesis, avoiding the chances of MBP-induced 
compaction of other portions of the cell and compromised survival.  Research into this problem 
revealed that oligodendrocytes transport MBP mRNA to relevant regions  of the cell via RNA 
binding proteins such as  hnRNP-1 and Kif1b (Lyons et al. 2009; Laursen et al. 2011).  MBP 
mRNA transport from the nucleus to specific sites of translation is one example of 
oligodendrocyte specialization; another is the active nuclear transport of Exon II-containing 
MBP isoforms.  Exon II contains coding of a nuclear localization sequence (NLS), and translated 
isoforms containing the NLS may have a role in the regulation of gene expression during 
development (Pedraza 1997). 
 Different molecules and growth factors were shown to stimulate oligodendrocyte 
maturation.  Platelet-derived growth factor (PDGF), basic fibroblast growth factor (bFGF), 
insulin-like growth factor-1 (IGF-1) and neurotrophin-3 (NT-3) stimulate OPC proliferation but 
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in the presence of triiodothyronine (T3), these cells differentiate into MBP expressing mature 
oligodendrocytes (Barres et al. 1994) .  
 Details of the molecular mechanisms underlying oligodendrocyte differentiation are 
still poorly understood.  In this regard, previous studies show that epigenetic mechanisms 
working through histone modification can modulate oligodendrocyte maturation (Copray et al. 
2009).  However, to our knowledge no studies have yet investigated the role of mechanisms 
related to DNA methylation.  This project began to investigate the potential role of MeCP2, a 
transcriptional regulator known to bind to methylated DNA.  As described below, this protein 
was originally thought to be exclusively expressed in cells of the neuronal lineage. 
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Figure 2: Markers in cells of oligodendrocyte lineage.  Beginning with precursor and moving 
clockwise, markers appear and disappear over the course of neural development.   CNP (or 
CNPase), MBP and MOG appear at different time points in maturation.  Modified from 
(Baumann and Pham-Dinh 2001).
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MeCP2, a multifunctional gene regulator 
 It is now well recognized that gene transcription and subsequent gene expression 
from DNA is in part regulated by epigenetic mechanisms, in which the DNA nucleotide 
sequence is unaltered, but the architecture of the molecule is modified in such a way so as to 
alter transcription.  Chromatin is the form of DNA and associated proteins in a non-dividing cell, 
and can exist as euchromatin, or the more condensed heterochromatin.  Euchromatin is the less 
condensed form of nuclear material, in which the DNA can be accessed by the transcriptional 
machinery of the cell; in contrast to heterochromatin, where the DNA molecule exists in varying 
states of compaction and cannot be transcribed.  Therefore, transcription can be regulated by 
changing the state of DNA between these two types of chromatin. 
 Condensation of DNA is in part affected by methylation of the phosphate-
deoxyribose backbone of the molecule.  CpG sites are dinucleotide sections of the DNA in which 
a cytosine is adjacent to a guanine in the sequence 5’-CpG-3’, also referred to as CpG islands.  
These sites are often methylated on the cytosine residue in a reversible reaction carried out by 
DNA methyltransferase enzymes.  Methyl-CpG binding domain (MBD) proteins interact with 
methylated-CpG islands and can modulate gene expression.  The MBD domain is located near 
the N-terminal region of these proteins.  The structure of this domain has been elucidated via x-
ray crystallography and NMR spectroscopy, and highly conserved residues of the N-terminal 
region were visualized as interacting in the major groove of the methylated CpG island (Ohki et 
al. 2001). 
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 Methylated-CpG-binding-protein-2 (MeCP2) is a nuclear protein that can act as a 
transcription repressor by binding to methylated DNA.  This protein contains an 84-aa MBD and 
a 104-residue TRD.  Human MeCP2 exists as two isoforms, the more common 486 aa protein or 
the 498 aa form.   Post-translational processing has been shown to include one or more 
serine/threonine phosphorylation sites as well as SUMO-1 modification, giving a molecular 
weight of 75 kDa in mouse and rat brain, and 100 kDa in human cerebral cortex(Jarrar et al. 
2003; Miyake and Nagai 2007).  Large sections of the protein lack any discernable secondary 
structures, such as beta sheets and alpha helixes (Hansen et al. 2010).  Lately, several 
observations have challenged the role of MeCP2 as a methyl-dependent repressor of 
transcription.  Upon binding to methylated DNA, MeCP2 recruits co-repressor proteins.  
However recent evidence has shown that MeCP2 binding to methylated DNA is only marginally 
greater than its binding to unmethylated DNA; human MeCP2 binds methylated DNA at only ~3 
fold the affinity with which this protein binds unmethylated DNA.  Additionally, MeCP2 has 
been implicated not in inhibition but in the promotion of activity of some genes(Chahrour et al. 
2008).  These findings have led to categorize MeCP2 as a gene modulator, and its effect on 
transcription being determined by other factors influencing the strength of the gene’s expression 
(Chahrour et al. 2008).  Furthermore, as later described in greater detail, recent studies have also 
shown that MeCP2 has a purported role in methyl-independent chromatin remodeling(Georgel et 
al. 2003), as well as a function in the regulation of RNA splicing (Young et al. 2005). 
  The MeCP2 gene is located at position Xq28, and mutations of this gene in the 
region encoding the MBD domain of the MeCP2 protein were shown to cause Rett’s 
syndrome(Amir et al. 1999), a cause of severe mental retardation in females.  In addition, Rett 
syndrome is characterized by autistic behavior, seizures, autonomic nervous system disorders, 
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stunted growth, gastrointestinal disorders, ambulatory and motor problems, and poor or 
nonexistent verbal skills.  The clinical severity of the illness has been linked to the activation of 
the affected X chromosome.  When the faulty gene is activated in a larger proportion of cells, the 
degree of mental retardation is more severe than that observed in patients with activation in a 
smaller proportion of cells (Archer et al. 2007).   MeCP2 mutation was once considered to be 
lethal in males, however this is now known to be incorrect, in fact a range of 
neurodevelopmental disorders are also encountered in males possessing a mutation of this gene 
(Villard 2007).    
  MeCP2 has been described as a protein highly expressed in neurons, but not in 
glial cells.  However, analysis of a MeCP2 knockout mouse have shown altered levels of myo-
inositol, a putative glial marker(Saywell et al. 2006).  Additionally, more recent studies of 
MeCP2 in astrocytes have shown that the protein is not only expressed in theses cells, but that 
their growth is inhibited when transfected with siRNA for MeCP2 (Nagai et al. 2005).  Clinical 
evidence has also pointed to the alteration of myelin in MeCP2-related illness.  White matter 
abnormalities in Rett syndrome patients have been documented for over twenty years (Oldfors 
1990).  More recent DTI studies in living patients have shown white matter abnormalities in the 
corpus callosum, external capsule, and other white matter tracts(Mahmood et al. 2010).  These 
studies taken together indicate a potential role of MeCP2 in oligodendrocytes. 
 Only one study so far has investigated myelin protein gene expression in a MeCP2 
knockout mouse. However, this recent report used an animal model in which the MeCP2 gene 
was eliminated by a nestin-Cre knockout mechanism. Because nestin is expressed in all neural 
progenitors, these animals lack MeCP2 expression in neurons and glial cells and thus the 
findings cannot be ascribed specifically to a direct role of MeCP2 in oligodendroglia.  A 
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reflection of the complexity of this system is the fact that changes in mRNA expression for 
myelin-related genes were region-specific.  Analysis of the mutant animals showed that in the 
case of MBP, higher levels of mRNA were detected in the corpus callosum and forebrain while 
levels in the cerebellum were unaffected.  Similarly, the results showed MAG mRNA levels in 
the corpus callosum of MeCP2null mice were three times higher than in the wild-type controls, 
though they were unaffected in forebrain and cerebellum.  PLP mRNA in the forebrain was 
significantly increased as well(Vora 2010).  This study did not indicate the relative levels of 
protein in this animal model, nor were actual levels of myelin protein measured.  Thus, the 
function of MeCP2 in oligodendrocytes and myelination has yet to be determined 
 Previous studies from this laboratory (Sato-Bigbee and Coelho 2009), that MeCP2 
may be involved in oligodendrocyte differentiation. In the present thesis, we have examined the 
role of MeCP2 in cultures of purified oligodendrocytes.  Our research not only indicates that 
MeCP2 is expressed in oligodendrocytes, but also that this protein plays a role in the maturation 
of these cells.  This novel finding, coupled with the role of MeCP2 mutation in Rett syndrome, 
may have implications for the understanding and future research into the pathology of this 
disease and other CNS disorders with altered MeCP2 expression. 
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Materials and Methods 
 
Materials  
 Percoll, bovine pancreas DNAse and papain for cell isolation as well as all cell 
culture medium components were purchased from Sigma-Aldrich (St. Louis, MO).  Dulbecco’s 
modified Eagle’s medium/ Ham’s F-12 (DMEM/F-12) (1:1) medium was obtained from 
Invitrogen (Grand Island, NY).  Reduced growth factor Matrigel was from Becton Dickinson 
(Franklin Lakes, NJ). All gel electrophoresis reagents and supplies were purchased from Bio-Rad 
Laboratories (Hercules, CA).  The mouse anti-β-actin and rat anti-MBP (82-87 region) 
monoclonal antibodies were from Sigma-Aldrich and Millipore Corporation (Temecula, CA), 
respectively.  The anti-MeCP2 polyclonal antibody (465-478 region) was purchased from 
Millipore Corporation (Temecula, CA).  Super Signal West Dura reagent was obtained from 
Pierce (Rockford, IL).  The secondary antibodies were purchased from Santa Cruz 
Biotechnology (Santa Cruz, CA) and Jackson ImmunoResearch Laboratories, Inc (West Grove, 
PA). 
 
Animals 
 Sprague-Dawley rats were provided by Harlan Laboratories (Frederick, MD). Animal 
use and oligodendrocyte isolation were conducted in accordance with the guidelines from the 
National Institutes of Health and approved by the Virginia Commonwealth University Animal 
Care and Use Committee. 
 
Isolation of pre-oligodendrocytes and preparation of cell cultures  
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 Pre-oligodendrocytes were directly isolated from 9-10 day-old rat brains as described 
previously (Colello and Sato-Bigbee 2001) with minor modifications. For this, the animals were 
sacrificed by decapitation and the brains rapidly dissected out, transferred to ice, and the 
meninges and main blood vessels removed by rolling the tissue on sterile filter paper. After 
mincing into 1-2 mm pieces, the tissue was incubated for 25 min. at 37oC in the presence of 1 
unit/ml papain and 0.01 mg/ml DNAse. Following extensive washes and filtration through a 
75µm pore size nylon mesh, the resulting cell suspension was centrifuged for 15 min at 30,000xg 
in an isotonic self-generated Percoll gradient.  The band enriched in oligodendrocytes was then 
subjected to differential adhesion on tissue culture-treated Petri dishes to eliminate microglial 
cells and residual astrocytes. The floating oligodendrocytes were then plated in 25-well plates 
(Falcon) previously coated with 25 µL/well reduced growth factor-MatrigelTM extracellular 
matrix. Prior to use, the cells were maintained overnight in chemically defined medium (CDM) 
(DMEM/F-12 supplemented with 1 mg/mL fatty acid-free bovine serum albumin, 50 µg/mL 
transferrin, 5 µg/mL insulin, 30 nM sodium selenite, 0.11 mg/mL sodium pyruvate, 10 nM 
biotin, 20 nM progesterone, 100 µM putrescine, and 30 nM triiodothyronine). Astroglial 
contamination, as assessed by glial fibrillary acid protein staining, was less than 5%. 
 
Analysis of MeCP2 expression at different stages of oligodendrocyte development 
To compare MeCP2 levels at different steps of oligodendrocyte maturation, cells were directly 
isolated from the rat brain as indicated above at 3, 5, 10, 18, and 25 days postnatal.  Equivalent 
numbers of cells were solubilized in 60 mM Tris-HCl buffer (pH 6.8) containing 10% glycerol, 
2% sodium dodecyl sulfate (SDS), and 5% 2-mercaptoethanol and maintained at -80 0C until 
further analysis by western blotting. 
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Inhibition of MeCP2 expression  
MeCP2 levels were downregulated in cultures of pre-oligodendrocytes one day after isolation 
from 9-10 rat brains as indicated above. For this, 80% confluent cell cultures were treated with 
MeCP2 specific siRNA duplexes (100 nM final concentration), designed using the 
“HiPerformance siRNA Design Algorithm” program from Quiagen (Bethesda, MD).  Double-
stranded scrambled non-functional /non-targeting siRNA was used as control.  Transfection of 
the RNAs was carried out for 3 hours by using the GeneJammer transfection reagent (Statagene, 
CA) following the manufacture's recommendations for cultured adherent cells (Saini et al. 
2005a).  At the end of the transfection procedure, the medium was replaced by fresh CDM.  Cell 
cultures under each condition were then examined for MeCp2 and myelin protein expression at 
the times indicated later in the text.  
 
Analysis of proteins by Western Blotting  
 Oligodendrocyte cultures were lysed in 50-75 µL 60 mM Tris-HCl buffer (pH 6.8) 
containing 10% glycerol, 2% SDS, and 5% 2-mercaptoethanol. After boiling for 5 minutes, 
proteins in 10 µL samples were then separated by SDS-polyacrylamide gel electrophoresis 
(PAGE) in 15% acrylamide and electro-transferred to nitrocellulose. The membranes were then 
subjected to immunoblot analysis as previously reported (Saini et al. 2005a), with minor 
modifications. Nonspecific antibody binding was blocked by incubation in 10 mM Na2HPO4, 2.7 
mM KCl and 137 mM NaCl, pH 7.4, (PBS) containing 3% nonfat-dry milk and 0.05% Tween-20 
(blocking solution), for 1 hr at room temperature. Blots were then incubated overnight with anti-
MeCp2 (dil. 1:1,000), anti-MBP (dil. 1:100), anti-CNPase (dil.1:1,000) or anti-MOG 
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(dil.1:1,000) antibodies. β-Actin levels detected with anti-β-actin antibody (dil. 1:5,000) were 
used as loading controls. After three 10 minute washes with PBS, blots were incubated for 30 
min in blocking solution, followed by incubation with the appropriate horseradish peroxidase 
(HRP)-conjugated secondary antibody for 2 hrs.  All antibodies were diluted in blocking buffer. 
At the end of the incubations blots were washed twice for 5 minutes with PBS containing 0.05% 
Tween-20 and four times for 10 minutes with PBS alone .The immunoreactive bands were then 
detected by chemiluminescence with Super Signal West Dura reagent. The relative amount of 
immunoreactive protein in each band was determined by scanning densitometric analysis of the 
X-ray films and the use of the NIH Image J program. The relative density values for each 
specific protein in question were divided by the corresponding β-actin levels to correct for total 
protein concentration and sample loading differences. 
 
Statistical Analysis 
 Statistical analysis was carried out by Student's T test using the GraphPad Prism 
program. Differences between results were considered statistically significant when p values 
were less than 0.05. 
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Results 
 
Analysis of MeCP2 expression at different stages of oligodendrocyte development 
 As described in the Introduction section, preliminary results from the laboratory 
detected the presence of MeCP2 in cultured oligodendrocytes and suggested a role in their 
maturation.  Thus, we have now continued those studies and determined the expression of this 
protein in oligodendrocytes in vivo and at different stages of brain development. Our initial 
studies using direct immunocytochemistry of brain tissue slices failed to clearly assess the extent 
of protein expression in the oligodendrocytes due to high staining in other cells and elevated 
background levels.  Therefore, we decided to solve this problem by investigating the 
developmental expression of MeCP2 in oligodendrocytes that were directed isolated from rat 
brain at different postnatal ages.  Previous studies from the laboratory (Sato-Bigbee et al. 1999a) 
determined that cells isolated from 3- to 5-day-old rat brain are immature OPCs, while cells from 
10-day-old animals belong to the pre-oligodendrocyte stage.  Cells obtained from 25-day-old rat 
brains are for the most part already mature myelinating oligodendrocytes. As shown in Figure 3, 
while MeCP2 is expressed at all developmental stages, the protein levels are the highest in the 
cells isolated from the 10-day-old pups, a pattern of expression that pointed to a functional role 
of MeCP2 as pre-oligodendrocytes are primed to mature into myelinating cells.  
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Figure 3:  MeCP2 levels at different stages of oligodendrocyte development.  
Oligodendrocyte lineage cells at different developmental stages were directly isolated from the 
rat brain at postnatal days 3 and 5 (OPCs), 10 (pre-oligodendrocytes), 18 (actively myelinating 
oligodendrocytes at the peak of rat brain myelination), and 26 (oligodendrocytes at the end of the 
active period of rat brain myelination). The relative OD values of MeCP2 for each of the samples 
were normalized by the corresponding OD values for actin.
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Analysis of MeCP2 function in pre-oligodendrocytes 
 Based on the developmental expression of MeCP2 in the oligodendrocytes described 
above, we next decided to investigate the function of this protein in pre-oligodendrocytes 
obtained from 9-10 day-old rat brain.  For this, the freshly isolated cells were plated at about 
80% confluence and on the following day, transfected with double-stranded siRNA specific to 
MeCP2 mRNA. Controls cultures were treated in a similar manner with a scrambled siRNA. 
Western blot analysis of the cells 24 hours after transfection showed that this treatment 
significantly reduces MeCP2 levels to about 50% of the control values (Figure 4). 
  
 We then tested whether cells with reduced MeCP2 levels exhibit any changes in the 
expression of different myelin-oligodendrocyte specific proteins that are expressed at different 
stages of cell maturation.  Pre-oligodendrocytes do not express MBPs but the synthesis of these 
proteins is upregulated as they differentiate into more mature cells. As shown in Figure 5, 
analysis of the different MBPs three days after transfection, indicated effects that were splicing 
variant-specific. No major changes were observed for the levels of the 17.0 kDa, 18.5 kDa, and 
21.5 kDa MBP isoforms while cell cultures treated with MeCP2 siRNA exhibited significantly 
reduced levels of the 14.0 kDa MBP.   
 We also chose to investigate MeCP2 involvement in the expression of CNPase, a 
protein that is already present in pre-oligodendrocytes and MOG, a glycoprotein that is expressed 
at the late stages of oligodendrocyte maturation. As shown in Figure 6, downregulation of 
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MeCp2 levels did not have any significant effects on the expression of CNPase. ).  Interestingly, 
cell cultures treated with MeCP2 siRNA exhibited significantly reduced levels of MOG.  
Because both the 14 kDa MBP and MOG are expressed in the mature oligodendrocytes, these 
results suggest that MeCP2 may play an important role in the last stages of oligodendrocyte 
differentiation. 
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Figure 4:  Inhibition of MeCP2 expression by siRNA treatment. Oligodendrocyte cultures 
prepared from cell directly isolated from 9-10-day-old rat brain were treated with MeCP2 siRNA 
as indicated under “Methods”. Control cultures were treated in a similar manner with scrambled 
siRNA. Western blot was used to detect MeCP2 expression 3 days after transfection. The 
western blot shows a representative experiment. The bar graph shows the mean + SEM from 3 
separate experiments. * p<0.003 
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Figure 5:  Analysis of MeCP2 function in pre-oligodendrocytes.  Pre-myelinating 
oligodendrocytes from 9-10 day old rat brains were treated with MeCP2 siRNA as indicated in 
“Methods”.  Controls were treated with scrambled siRNA.  Western blots were used to detect 
MBP protein levels three days post transfection.  A representative western blot is shown.  The 
columns indicate the mean ± SEM from 9 experiments.  ** p<0.005 
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Figure 6:  Analysis of MeCP2 function in pre-oligodendrocytes.  Pre-myelinating 
oligodendrocytes from 9-10 day old rat brains were treated with MeCP2 siRNA as indicated in 
“Methods”.  Controls were treated with scrambled siRNA.  Western blots were used to detect 
CNPase and MOG protein levels three days post transfection.  A representative western blot is 
shown.  The columns indicate the mean ± SEM from 6 experiments.  * p<0.05 
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Discussion 
 
  Previous research into MeCP2 function in Rett syndrome and autism-related disorders 
has been focused primarily on neurons, however, autopsies have shown the presence of white 
matter abnormalities in the brains of Rett syndrome patients, and recent fMRI studies in Rett 
syndrome patients reinforce these studies (Oldfors 1990; Mahmood et al. 2010).  Furthermore, as 
described in the introduction a recent report indicated that MeCP2null mice exhibit region-specific 
alterations in the levels of mRNA for different myelin proteins(Vora 2010).    While myelin-
related problems in both patients and the animal model could reflect neuronal alterations 
affecting both axon outgrowth and axo-glial interactions, the finding of MeCP2 presence in 
oligodendrocytes and our present observations raise the possibility that this protein may also play 
a crucial direct role in these cells controlling myelin formation.  
 Our findings indicate that MeCP2 is present in oligodendrocytes during the period of 
active rat brain myelination. Moreover, downregulation of MeCP2 levels in cultured 
oligodendrocytes has differential effects on the expression of myelin specific proteins that are 
suggestive of a role of MeCP2 in oligodendrocyte maturation.  The proteins that we have 
examined in this study place the importance of MeCP2 function in the last stages of 
oligodendrocyte development.  MOG as well as the 14 kDa MBP isoform are unique in that they 
are expressed later in myelin formation and we have found that their levels are significantly 
reduced in the cells in which MeCP2 expression is downregulated.  Understanding of the 
mechanisms underlying these effects is complicated by the fact that several recent publications 
uncovered multiple roles of MeCP2 that expand well beyond its originally proposed function as a 
transcriptional repressor (Newell-Price et al. 2000; Georgel et al. 2003; Nagai et al. 2005; Wade 
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2005; Nikitina et al. 2007; Yasui et al. 2007; Chahrour et al. 2008).  Based on these multiple 
functions, possible reasons for the effects we observed in the oligodendrocytes may include: (1) 
a role for MeCP2 in the silencing of genes which could in turn downregulate MOG and 14KDA 
MBP expression; (2), a role for MeCP2 as a transcriptional activator perhaps working in 
conjunction with other transcription factors important for oligodendrocyte development; (3), a 
potential function in the splicing of the Golli-MBP gene, and/or a role in the expression of 
transport proteins responsible for the movement of MBP mRNA to the oligodendrocyte 
processes; and (4), a MeCP2 function in large-scale chromatin remodeling independent of 
methylated DNA binding.  
  It has been previously shown that in neurons, MeCP2 seems to function as a 
developmental brake, slowing down some processes important for cell maturation (Carter and 
Segal 2001).  One possibility in the oligodendrocytes is the function of MeCP2 in gene silencing 
via methylation-dependent recruitment of histone deacetylases (HDACs).  Gene silencing 
through the binding of methylated CpG sites may be the most easily modeled way in which 
MeCP2 downregulation affects the expression of myelin proteins.  As previously discussed, 
MeCP2 was first shown to be involved in the silencing of genes by a mechanism in which a 
protein complex including Sin3A, HDAC, and MeCP2 attaches to methyl-CpG groups utilizing 
the methyl binding ability of MeCP2.  This localization allows HDAC in complex with MeCP2 
to remove the acetyl groups from nearby histone proteins, thus promoting compaction of 
chromatin and by extension silencing local gene expression (Wade 2005).  Based on our present 
results, it is possible to speculate that a DNA-methylation dependent gene silencing mechanism 
mediated by MeCP2 may be indirectly responsible for controlling the observed results on the 
level of MOG and 14 kDa MBP protein levels in the oligodendrocyte. This could be the case if 
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MeCP2 binds to and silences genes encoding products which somehow maintain the 
oligodendrocytes in a less mature stage of development. While such possibility has not been 
investigated before, there is indeed evidence for the existence of negative regulators of 
oligodendrocyte maturation.  Among these proteins, Hes-5 is a transcription factor expressed in 
neural cells which inhibits oligodendrocyte differentiation and is controlled by a promoter region 
with multiple CG rich regions (Takebayashi et al. 1995).  MeCP2 has not been associated with 
Hes-5 expression, but this has not been investigated, and could be a possible mechanism 
responsible for our observed results.  
 Another possibility to explain our present findings is a function of MeCp2 as a 
transcriptional activator. Evidence has emerged in the last half-decade which questions the 
exclusive role of MeCP2 as a gene repressor as MeCP2-promoter binding has been shown to 
increase expression of certain genes. Genomic analysis of hypothalami from six-week old wild-
type, MeCP2null and MeCP2 over-expressing mice demonstrated that 85% of the genes showing 
altered activity exhibited increased expression in the MeCP2 over-expressing mutants. On the 
contrary, these genes showed decreased expression in the MeCP2null mice (Chahrour et al. 2008). 
Thus, the classic role for MeCP2 as a silencer of gene expression is still correct in some cases, 
but the protein is increasingly being characterized as a gene "modulator" that can work both as 
inhibitor or activator.  
 The mechanisms underlying MeCP2 function as a positive regulator of gene 
expression are still being determined, but some models have been substantiated. It has been 
shown that MeCP2 associates with CREB1, an activator of gene expression.   The MBD of 
MeCP2 has been shown as necessary for this particular mechanism of gene enhancement.   A 
genome-wide study has shown upregulation of a multitude of genes, including the activation of 
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CREB1 which in turn increases expression of the micro-RNA miR134.  This micro-RNA 
downregulates the expression of MeCP2; and so a negative-feedback mechanism may regulate 
expression of these molecules (Chahrour et al. 2008).  Interestingly, previous results from this 
laboratory have implicated CREB as a mediator of a variety of signals that regulate 
oligodendrocyte development (Sato-Bigbee and DeVries 1996; Sato-Bigbee et al. 1999b; Afshari 
et al. 2001; Saini et al. 2004; Saini et al. 2005b).  Moreover, CREB was shown to play a crucial 
role regulating MBP gene expression (Sato-Bigbee and DeVries 1996; Afshari et al. 2001) 
although this gene lacks CREB binding sites. Thus, it is tempting to hypothesize that both 
MeCP2 and CREB could be part of a common mechanism that could indirectly stimulate MBP, 
and perhaps also MOG, gene activities. 
 Particularly intriguing is the fact that MeCP2 downregulation was accompanied by a 
decrease in the 14 kDa MBP levels without majorly affecting the expression of the other MBP 
splicing isoforms.  As discussed previously, the 14 kDa MBP is characteristic of mature 
oligodendrocytes and thus, its reduced expression in the cells with decreased MeCP2 levels may 
be a reflection of a general effect of MeCP2 in cell development.   However, different reports 
investigating novel roles of this multifaceted modulator also raise the possibility of direct 
MeCP2 effects on gene splicing.  MeCP2 was shown to associate with the RNA splicing factor 
YB-1 in a specific and RNA dependent manner, and modification to remove the DNA methyl-
binding properties of the MBD in MeCP2 did not prevent this association (Young et al. 2005).  
YB-1 is one of the most highly conserved DNA binding proteins (Kohno et al. 2003) and one of 
its functions includes controlling the alternative splicing of mRNA for the cell adhesion 
molecule CD44.  Experiments in MeCP2 over-expressing HeLa cells demonstrated that this 
function does not involve changes in YB-1 levels, ruling out indirect effects on gene splicing by 
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transcriptional regulation of the YB-1 gene (Young et al. 2005).  Another factor that was shown 
to associate with MeCP2 in the rat brain is the hnRNP TDP-43.  TDP-43 is involved in splicing 
of mRNA during synapse formation, neuron development and RNA processing, including pre-
mRNA splicing, mRNA transport and stability (Buratti 2008; Sephton et al. 2011). To our 
knowledge, none of these splicing factors have been studied in oligodendrocytes, however it 
would be interesting to examine a potential role of MeCP2 and these proteins in these cells.  We 
cannot discard the possibility that MeCP2 may associate with other RNA binding proteins 
known to be involved in myelin synthesis, such as hnRNP A1, a protein known to participate in 
the intracellular transport of MBP mRNA in oligodendrocytes (Shan et al. 2000).  As TDP-43 is 
a related molecule, investigation of a potential association between hnRNP A1 and MeCP2 may 
be useful in elucidating a mechanism of MeCP2-mediated RNA processing. 
 Finally, another potential mechanism of MeCP2 function is large-scale chromatin 
remodeling independent of methylated DNA binding.  Large-scale modifications of chromatin, 
such as looping, may be the primary method by which MeCP2 could affect MOG and 14KDA 
MBP protein levels during development.  It has been demonstrated that the shape of nucleoli and 
heterochromatic chromocenters is significantly altered in neurons lacking MeCP2 (Singleton et 
al. 2011).  In vitro experiments have shown that MeCP2 compacts nucleosomes into secondary 
chromatin structures, and does so importantly in the absence of salts (as well as in the presence 
of physiological salt concentrations).  The remodeling is distinct from the methylated CpG 
binding/deacetylation role as the binding sites for MeCP2 in these examples are often 
unmethylated (Yasui et al. 2007) and missense and nonsense mutants in which the MBD of 
MeCP2 has been affected do not cause loss of chromatin condensation induced by this protein 
(Georgel et al. 2003). Two high-mobility group domains have been implicated in this property of 
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MeCP2, which is also unaffected by the presence of methyltransferase inhibitors. These 
chromatin modifications cannot be classified as uniformly downregulatory or upregulatory, but 
they further substantiate the theory that MeCP2 is in fact a modulator of gene expression.  Thus, 
it would be important to determine if downregulation of MeCP2 expression in our experiments is 
accompanied by changes in chromatin remodeling in the oligodendrocytes and the extent to 
which such changes could regulate myelin protein expression.  
 An important consideration is that the functions described above for MeCP2 are not 
mutually exclusive, and in developing oligodendrocytes this protein may be performing a 
combination of several of the regulatory mechanisms described above (Figure x ).  Maturing 
oligodendrocytes and myelination are subjected to a myriad of regulatory mechanisms and at this 
moment it is difficult to ascertain if any of them could at the same time determine a prefer 
MeCP2 mode of action. As research continues on the increasingly complex role that MeCP2 
plays in epigenetics, gene splicing and other gene expression mechanisms, it seems likely that 
any cell type which expresses this protein will exhibit substantial developmental abnormalities 
when afflicted with a mutation in the MeCP2 gene.   
 Regardless of the mechanism, the findings presented in this thesis provide for the first 
time direct support for an important role of MeCP2 in the control of oligodendrocyte 
development and myelination. Future experiments should investigate if the role of MeCP2 found 
in the cultured cells is also observed in vivo and the extent to which this protein function in 
oligodendrocytes could contribute to the developmental alterations and symptoms observed in 
Rett syndrome and autism-related disorders with abnormal MeCP2 expression.  From a clinical 
point of view, future studies should also consider how adverse expression or function of MeCP2 
in cells of the nervous system other than oligodendrocytes may indirectly affect CNS 
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myelination. Altogether, these studies could also contribute to the design of strategies that either 
by pharmacological intervention or genetic manipulation may stimulate remyelination in 
demyelinating diseases like multiple sclerosis.  
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Figure 7:  Hypothetical mechanisms by which MeCP2 increases myelin protein expression.  
A) Methylated DNA dependant gene repression.  The MBD of MeCP2 localizes the protein to a 
region of the DNA molecule which regulates expression of Factor X, a downregulator of MOG 
transcription.  Factor X would be an oligodendrocyte development inhibitor such as Id2 or Id4.  
This mechanism allows MeCP2 to indirectly enhance myelin protein expression  B) Metylated 
DNA-dependant myelin protein enhancement.  The MBD of  MeCP2 localizes it to a DNA 
region where the protein directly upregulates transcription.  C)  RNA splicing.  MeCP2 
associates with a splicing factor similar to TDP-43, facilitating myelin protein pre-mRNA 
processing.  D)  Large scale chromatin remodeling.  MeCP2 causes major structural changes in 
the architecture of chromatin, in this diagram placing the MOG gene in a conformation where it 
can be accessed by transcription mechanisms.  Importantly MeCP2 may instead change 
chromatin in such a way as to downregulate transcription of myelin protein downregulators, such 
as Id2 or Id4. 
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